clinical trial · NCT06847464
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
Enanta Pharmaceuticals, Inc·phase1·completed·n = 48
RSV InfectionDrug Drug Interaction (DDI)EDP-323ItraconazoleEDP-323carbamazepineEDP-323QuinidineEDP-323fluconazole
brief summary
The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled.
started
Jan 27, 2025
primary completion
May 24, 2025
completion
Jun 1, 2025
last updated
Jul 1, 2025
official title
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine, and Fluconazole on the Pharmacokinetics and Safety of EDP-323 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol